Exelixis
EXEL
#1728
Rank
C$16.37 B
Marketcap
C$61.09
Share price
-0.36%
Change (1 day)
17.13%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): C$4.01

According to Exelixis's latest financial reports the company's current EPS (TTM) is C$4.02. In 2023 the company made an earnings per share (EPS) of C$0.91 an increase over its 2022 EPS that were of C$0.79.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)C$4.01
2023C$0.9114.61%
2022C$0.79-22.97%
2021C$1.03100%
2020C$0.52-65.09%
2019C$1.48-53.91%
2018C$3.20333.96%
2017C$0.74-260.61%
2016C-$0.46-58.75%
2015C-$1.11-42.45%
2014C-$1.945.3%
2013C-$1.84

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
C$15.51 285.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
C$1.89-52.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
C$19.95 395.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
C$2.88-28.54%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
C$10.18 152.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$4.82 19.72%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
C$5.25 30.38%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
C-$5.11-226.99%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
C-$1.17-129.07%๐Ÿ‡บ๐Ÿ‡ธ USA